Pharmaceutical

Immunocore and BMS partner to investigate first-line treatment for melanoma

The company will evaluate an IMC-F106C/Opdivo combination treatment in a Phase III registrational study called PRISM-MEL-301.

Feb 22, 2024 - 18:00
Immunocore and BMS partner to investigate first-line treatment for melanoma
The company will evaluate an IMC-F106C/Opdivo combination treatment in a Phase III registrational study called PRISM-MEL-301.
Read the original article

Tags:

Previous Article

Digital transformation of the supply chain will make data more valuable – are yo...

Next Article

Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Can exercise help treat long Covid? New study finds patients improve with self-paced approach

Can exercise help treat long Covid? New study finds pat...

Feb 7, 2024

Container Closure Integrity Testing (CCIT): How to get started with deterministic methods

Container Closure Integrity Testing (CCIT): How to get ...

Mar 29, 2023

Arizona plans to dramatically increase hepatitis C testing and treatment in prisons

Arizona plans to dramatically increase hepatitis C test...

Mar 20, 2023